| HOME >> MEDICINE >> TECHNOLOGY |
NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- On August 7, J. J. Finkelstein, Chief Executive Officer of RegeneRx Biopharmaceuticals (Amex: RGN) updated the investment community in an all-new interview with http://www.wallst.net. Topics covered in the interview include RegeneRx Biopharmaceuticals' clinical trials, market potential, competitive edge, recent news, and milestones for which investors should watch.
To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.
About RegeneRx Biopharmaceuticals:
RegeneRx, headquartered in Bethesda, Maryland, is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. The Company is currently sponsoring five clinical trials for dermal wound healing, ophthalmic wound healing, and cardiovascular protection and regeneration after heart attack.
RegeneRx utilizes an outsourcing business model in order to effectively control costs while focusing on clinical development of its drug candidates. This model is used for research and development, manufacturing, drug formulation and clinical trials, as well as for other functions critical to its mission and enhances RegeneRx's ability to allocate resources rapidly to different projects without having to invest in infrastructure.
For more information about this Company, please visit http://www.regenerx.com.
About WallSt.net:
http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site. Financial Filings Corp. has received two hundred eighty dollars from RegeneRx Biopharmaceuticals, Inc. as reimbursement for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)
Contact: WallSt.net
800-4-WALLST
'/>"/>
SOURCE Financial Filings Corp. Copyright©2007 PR Newswire. |
Related medicine technology :
1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Tercica to Present at Investment Conferences
7. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
8. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
11. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |